Fatigue News and Research RSS Feed - Fatigue News and Research

NPS MedicineWise launches new diagnostic approach for fatigue

NPS MedicineWise launches new diagnostic approach for fatigue

Fatigue is a common complaint accounting for around 3-7% of all presentations to general practitioners. To help health professionals understand the limitations and appropriate use of diagnostic tests relating to fatigue NPS MedicineWise has launched a new program—Back to basics for fatigue: a diagnostic approach. [More]
Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Reducing insomnia can decrease inflammation, lower risk for chronic disease in older adults

Lack of sleep can make you sick. And while everybody has the occasional restless night, for those who suffer from chronic insomnia — some 15 percent of older adults in the United States — that sleep loss can increase the risk for cardiovascular disease, hypertension, weight gain, type 2 diabetes, and even lead to an earlier death. [More]
Scientists develop first blood test to diagnose major adult depression

Scientists develop first blood test to diagnose major adult depression

The first blood test to diagnose major depression in adults has been developed by Northwestern Medicine- scientists, a breakthrough approach that provides the first objective, scientific diagnosis for depression. [More]
Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). [More]
Ramucirumab effective second-line option for NSCLC

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial. [More]
Study links slowed processing speed with executive deficits in individuals with multiple sclerosis

Study links slowed processing speed with executive deficits in individuals with multiple sclerosis

Kessler Foundation researchers have published a study supporting the role of slowed processing speed in the executive deficits found in individuals with multiple sclerosis (MS). [More]
Warwick researchers discover novel drug target for treating postpartum haemorrhage

Warwick researchers discover novel drug target for treating postpartum haemorrhage

Researchers at the University of Warwick have discovered a new target for drugs that could prevent the deaths of thousands of women in the developing world due to heavy blood loss after childbirth. [More]
Thoracic radiotherapy reduces cancer recurrence in SCLC patients, shows new study

Thoracic radiotherapy reduces cancer recurrence in SCLC patients, shows new study

Treating advanced small-cell lung cancer (SCLC) with thoracic (or chest) radiation therapy in addition to standard treatment significantly prolongs long-term survival and reduces cancer recurrence in the chest by almost 50%, according to new research published in The Lancet and being presented simultaneously at ASTRO's 2014 Annual Meeting in San Francisco. [More]
Viewpoints: Crediting the health law for modest premium increases; Hollywood misses the mark on sick teens

Viewpoints: Crediting the health law for modest premium increases; Hollywood misses the mark on sick teens

The rate of growth on premiums for employer-based health coverage in the first five months of this year was one of the lowest in 16 years. Despite longstanding concerns that employer-sponsored coverage might become too costly to sustain, that market seems to have stabilized for now .... Thanks to the Affordable Care Act, federal tax credit subsidies -; available for people earning up to 400 percent of the federal poverty level ($95,400 for a family of four) -; are helping to make these policies affordable and cushioning the impact of premium increases in some cities (9/14). [More]
Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. [More]
Simple point-of-care testing device provides more rapid diagnosis of anemia

Simple point-of-care testing device provides more rapid diagnosis of anemia

A simple point-of-care testing device for anemia could provide more rapid diagnosis of the common blood disorder and allow inexpensive at-home self-monitoring of persons with chronic forms of the disease. [More]

Vuzix, Rochester collaborate to prescribe fashion frames, lenses for M100 Smart Glasses wearers

Vuzix® Corporation, a leading supplier of Video Eyewear and Smart Glasses products in the consumer, commercial and entertainment markets, announced today a strategic collaboration with Rochester Optical to provide fashion frames and prescription lenses for M100 Smart Glasses wearers. [More]
Working memory may be underlying mechanism of cognitive reserve in MS

Working memory may be underlying mechanism of cognitive reserve in MS

Kessler Foundation scientists have shown that working memory may be an underlying mechanism of cognitive reserve in multiple sclerosis (MS). [More]

Researchers find that shared pain can boost actual group cooperation

What doesn't kill us may make us stronger as a group, according to findings from new research published in Psychological Science, a journal of the Association for Psychological Science. [More]
Researchers examine whether new drug offers added benefit for patients with chronic HCV

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection. [More]
Ortho-oncology team successfully adapts shoulder surgical aid

Ortho-oncology team successfully adapts shoulder surgical aid

An ortho-oncology team at Dartmouth-Hitchcock Norris Cotton Cancer Center successfully adapted a shoulder surgical aid (the Spider Limb Positioner) to conduct a left hip disarticulation on a melanoma patient as described in a case report published online in Medical Devices. [More]
FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). [More]
White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

A little white pill may help scientists learn why patients with cystic fibrosis have less exercise capacity than their peers, even if their lungs are relatively healthy. [More]
Yoga program for MS patients improves physical and mental well-being

Yoga program for MS patients improves physical and mental well-being

Paula Meltzer was only 38 when out of nowhere everything she looked at was blurry. For the single mother, who had a lucrative career as a gemologist and spent hours examining valuable pieces of jewelry, it seemed as if - in a split second - her life changed. [More]
MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). [More]